0.83
14.66%
0.1061
After Hours:
.85
0.02
+2.41%
Karyopharm Therapeutics Inc stock is traded at $0.83, with a volume of 1.77M.
It is up +14.66% in the last 24 hours and up +9.18% over the past month.
Karyopharm Therapeutics Inc is a commercial-stage pharmaceutical company pioneering novel cancer therapies and dedicated to the discovery, development, and commercialization of drugs directed against nuclear export for the treatment of cancer and other diseases. XPOVIO (selinexor), is approved in the U.S. in multiple hematologic malignancy indications, including in combination with Velcade (bortezomib) and dexamethasone for the treatment of adult patients with multiple myeloma after at least one prior therapy, in combination with dexamethasone for the treatment of adult patients with heavily pretreated multiple myeloma and as a monotherapy for the treatment of adult patients with relapsed or refractory diffuse large B-cell lymphoma. The company derives its revenue from United States.
See More
Previous Close:
$0.7239
Open:
$0.726
24h Volume:
1.77M
Relative Volume:
1.82
Market Cap:
$98.75M
Revenue:
$140.46M
Net Income/Loss:
$-146.34M
P/E Ratio:
-0.6288
EPS:
-1.32
Net Cash Flow:
$-117.73M
1W Performance:
+18.91%
1M Performance:
+9.18%
6M Performance:
-45.03%
1Y Performance:
-38.06%
Karyopharm Therapeutics Inc Stock (KPTI) Company Profile
Name
Karyopharm Therapeutics Inc
Sector
Industry
Phone
617-658-0600
Address
85 WELLS AVENUE, NEWTON, MA
Karyopharm Therapeutics Inc Stock (KPTI) Upgrades & Downgrades
Date | Action | Analyst | Rating Change |
---|---|---|---|
Jan-19-23 | Initiated | Piper Sandler | Overweight |
Nov-04-22 | Upgrade | RBC Capital Mkts | Sector Perform → Outperform |
Feb-09-22 | Upgrade | JP Morgan | Underweight → Neutral |
Nov-19-21 | Resumed | Morgan Stanley | Equal-Weight |
Aug-06-21 | Downgrade | JP Morgan | Overweight → Neutral |
Aug-06-21 | Downgrade | RBC Capital Mkts | Outperform → Sector Perform |
Aug-06-21 | Downgrade | SVB Leerink | Outperform → Mkt Perform |
Jul-02-20 | Initiated | Morgan Stanley | Overweight |
Mar-04-20 | Initiated | Barclays | Overweight |
Jan-17-20 | Downgrade | Wedbush | Outperform → Neutral |
Jul-23-19 | Upgrade | JP Morgan | Neutral → Overweight |
Jul-05-19 | Reiterated | H.C. Wainwright | Buy |
Jul-05-19 | Reiterated | Robert W. Baird | Outperform |
Mar-01-19 | Downgrade | JP Morgan | Overweight → Neutral |
Feb-28-19 | Reiterated | BofA/Merrill | Underperform |
Feb-27-19 | Downgrade | BofA/Merrill | Neutral → Underperform |
Jan-03-19 | Upgrade | BofA/Merrill | Underperform → Neutral |
Dec-03-18 | Initiated | B. Riley FBR | Buy |
Nov-09-18 | Upgrade | Wedbush | Neutral → Outperform |
May-24-18 | Downgrade | Wedbush | Outperform → Neutral |
Apr-02-18 | Resumed | Leerink Partners | Outperform |
Nov-15-17 | Resumed | H.C. Wainwright | Buy |
Sep-15-17 | Initiated | RBC Capital Mkts | Outperform |
Sep-08-16 | Reiterated | H.C. Wainwright | Buy |
Aug-30-16 | Upgrade | Jefferies | Hold → Buy |
Aug-18-16 | Initiated | H.C. Wainwright | Buy |
Jun-28-16 | Initiated | Robert W. Baird | Outperform |
View All
Karyopharm Therapeutics Inc Stock (KPTI) Latest News
Financial Snapshot: Analyzing Karyopharm Therapeutics Inc (KPTI)’s Key Ratio Metrics - The Dwinnex
A new trading data show Karyopharm Therapeutics Inc (KPTI) is showing positive returns. - SETE News
SVP, General Counsel&Secretary Mano Michael sold 3,971 shares of Karyopharm Therapeutics Inc [KPTI] - Knox Daily
Karyopharm Therapeutics Inc (KPTI) Performance and Fundamentals Dashboard tells a completely different story - SETE News
The Globe and Mail - The Globe and Mail
A stock that deserves closer examination: Karyopharm Therapeutics Inc (KPTI) - US Post News
Metric Deep Dive: Understanding Karyopharm Therapeutics Inc (KPTI) Through its Ratios - The Dwinnex
KJTS Group shares climb to near six-week high after contract win - The Edge Malaysia
Market Movers to Watch: Black Diamond (Nasdaq: BDTX), Peraso Inc. (NASDAQ: PRSO), Kaival Brands (NASDAQ: KAVL) among others w/Key Announcements - Barchart
KEC International Shares Surge 3% on Securing Orders Worth Rs 1,003 Crore - EquityPandit
KEC International Boosts Market Presence with Rs 1,003 Crore New Contracts - PUNE.NEWS
KEC International surges 3% after bagging orders worth Rs 1,003 cr; details - Business Standard
India's KEC International rises on 10.03 bln rupee order wins - XM
KEC International shares surge 4% on new orders worth Rs 1,003 crore - Moneycontrol
Acadian Asset Management LLC Invests $167,000 in Karyopharm Therapeutics Inc. (NASDAQ:KPTI) - Defense World
KEC International down 5% as CARE Ratings downgrades co's bank facilities - Business Standard
KEC International shares drop 4% after credit rating downgrade by CARE - Business Upturn
5:1 Stock Split Announced by This Multibagger Smallcap Company- Stock Hits 52-Week High Today, Gains Over 1,000 Per cent Returns in Just 1 Year! - Dalal Street Investment Journal
KHPT unveils ACE Market IPO prospectus to raise up to RM29 mil - The Edge Malaysia
Karyopharm faces Nasdaq delisting over share price woes By Investing.com - Investing.com Australia
Karyopharm faces Nasdaq delisting over share price woes - Investing.com India
Karyopharm faces Nasdaq delisting over share price woes - Investing.com
Karyopharm faces Nasdaq delisting over share price woes By Investing.com - Investing.com South Africa
Karyopharm Therapeutics Inc. (NASDAQ:KPTI) Receives $4.80 Consensus Target Price from Brokerages - MarketBeat
Kross Soars 11% In Debut Trade - Bizz Buzz
Karyopharm Therapeutics Inc. (NASDAQ:KPTI) Given Average Recommendation of “Moderate Buy” by Analysts - Defense World
Karyopharm Therapeutics Inc’s Market Journey: Closing Strong at 0.76, Up 3.85 - The Dwinnex
Karyopharm Therapeutics Inc (KPTI) Becoming More Attractive for Investors - Knox Daily
Karyopharm to Participate at Upcoming Investor Conferences - Kilgore News Herald
Piper Sandler initates Karyopharm Therapeutics Inc (KPTI) stock to an Overweight - Knox Daily
Karyopharm Therapeutics (NASDAQ:KPTI) Share Price Passes Below 200-Day Moving Average of $1.06 - MarketBeat
Karyopharm Therapeutics (NASDAQ:KPTI) Stock Crosses Below Two Hundred Day Moving Average of $1.06 - Defense World
Analysts Update Their Estimates For Karyopharm Therapeutics Inc - Stocks Register
Karyopharm Therapeutics Inc (KPTI) Stock: A Comprehensive 52-Week Review - The InvestChronicle
Down -12.14% in 4 Weeks, Here's Why Karyopharm Therapeutics Looks Ripe for a Turnaround - Benzinga
KPTI Shares Experience Decline in Value - Knox Daily
Karyopharm Therapeutics Inc (KPTI) Clearly Signals Buy-Into the Stock: Don’t ignore the signals - SETE News
Down -12.14% in 4 Weeks, Here's Why Karyopharm Therapeutics (KPTI) Looks Ripe for a Turnaround - Yahoo Finance
Karyopharm Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - StockTitan
Karyopharm to Participate at Upcoming Investor Conferences - StockTitan
An Analysis of Karyopharm Therapeutics Inc (KPTI)’s Potential Price Growth - Knox Daily
Karyopharm Therapeutics (NASDAQ:KPTI) Stock Passes Below Two Hundred Day Moving Average of $1.09 - MarketBeat
KPTI stock rated an Overweight by Piper Sandler - Knox Daily
Contrasting Karyopharm Therapeutics (NASDAQ:KPTI) and Zai Lab (NASDAQ:ZLAB) - Defense World
Take off with Karyopharm Therapeutics Inc (KPTI): Get ready for trading - SETE News
Are Options Traders Betting on a Big Move in Karyopharm Therapeutics (KPTI) Stock? - Yahoo Movies UK
Analysts Set Karyopharm Therapeutics Inc. (NASDAQ:KPTI) PT at $4.80 - MarketBeat
Karyopharm Therapeutics (NASDAQ:KPTI) Stock Price Passes Below Two Hundred Day Moving Average of $1.12 - MarketBeat
Karyopharm Therapeutics Inc (KPTI) requires closer examination - US Post News
KPTI (Karyopharm Therapeutics) Revenue : $145.7 Mil (TTM As of Jun. 2024) - GuruFocus.com
Karyopharm Reports First Quarter 2024 Financial Results and Highlights Recent Company Progress - Longview News-Journal
Karyopharm Therapeutics Inc Stock (KPTI) Financials Data
Revenue
Net Income
Cash Flow
EPS
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):